Impact of ivabradine in decompensated heart failure due to cancer therapy-related cardiac dysfunction
Yusuke Nakano1, Hirohiko Ando1, Wataru Suzuki1
1Department of Cardiology Aichi Medical University Nagakute Japan.
Abstract:
In cases of decompensated heart failure related to cancer therapy-related cardiac dysfunction, ivabradine administration could lead to an increased stroke volume by reducing the sinus heart rate, resulting in favorable hemodynamics. Assessment of the overlap between the E- and A-waves facilitates understanding the effects of ivabradine in such cases.
More Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
14:24Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure VI: Adjunct Therapies
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: β-Blockers
Heart Failure III: Clinical Manifestations
Heart Failure II: Pathophysiology
